Tag: NIH license
Vaxxas to develop first room-temperature stable RSV vaccine with NIH license
Vaxxas, a clinical-stage biotechnology company known for its innovative high-density microarray patch (HD-MAP) vaccination platform, has secured a worldwide license from the United States National Institutes of Health (NIH) for a next-generation vaccine antigen aimed at combating Respiratory Syncytial Virus (RSV).
Featured Article
Good Design Australia opens entries for 2026 awards
For more than six decades, Good Design Australia has celebrated the power of design to shape innovation, industry, and everyday life. Its flagship program, the Australian Good Design Awards, recognises projects that show how thoughtful design can enhance products, services, systems, and communities.
